Investing.com - Castle Biosciences (NASDAQ: CSTL) reported fourth quarter EPS of $-0.10, $0.48 better than the analyst estimate of $-0.58. Revenue for the quarter came in at $66.12M versus the consensus estimate of $55.02M.
Guidance
Castle Biosciences sees FY 2024 revenue of $235.00M-$240.00M versus the analyst consensus of $214.70M.
Castle Biosciences's stock price closed at $24.39. It is up 22.13% in the last 3 months and up 6.69% in the last 12 months.
Castle Biosciences saw 4 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Castle Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, Castle Biosciences's Financial Health score is "good performance".
Check out Castle Biosciences's recent earnings performance, and Castle Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar